Burden of Chemotherapy Induced Febrile Neutropenia and Role of G-CSF in Febrile Neutropenia in a Low-Income Country: The Children's Hospital Lahore Pakistan Experience

被引：0
|
作者：
Ahmad, A. [1 ,2 ]
Khan, F. S. [3 ,4 ]
Sadiq, M. [3 ,5 ]
机构：
[1] Children Hosp, Lahore, Pakistan
[2] Inst Child Hlth Lahore, Paediat Haematol Oncol, Lahore, Pakistan
[3] Childrens Hosp, Lahore, Pakistan
[4] Inst Child Hlth Lahore Pakistan, Paediat Haematol, Lahore, Pakistan
[5] Inst Child Hlth Lahore Pakistan, Lahore, Pakistan
来源：
PEDIATRIC BLOOD & CANCER | 2018年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O-052
引用
收藏
页码：S31 / S31
页数：1
相关论文
共 50 条
  • [41] The safety of full-dose chemotherapy with secondary prophylactic granulocyte colony stimulating factor (G-CSF) following a prior cycle with febrile neutropenia
    Nissim Haim
    Katerina Shulman
    Hadassah Goldberg
    Medy Tsalic
    Medical Oncology, 2005, 22 : 229 - 232
  • [42] Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Adult Patients with Lymphoproliferative Disorders - Clinical Experience in University Hospital of Split
    Galusic, Davor
    Petric, Marija
    Cutura, Lucana Vicelic
    Miljak, Antonija
    Blaslov, Viktor
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S242 - S243
  • [43] Incidence of Febrile Neutropenia and Myelotoxicity of Chemotherapy: A Meta-Analysis of Biosimilar G-CSF Studies in Breast Cancer, Lung Cancer, and Non-Hodgkin's Lymphoma
    Engert, Andreas
    del Giglio, Auro
    Bias, Peter
    Lubenau, Heinz
    Gatzemeier, Ulrich
    Heigener, David
    ONKOLOGIE, 2009, 32 (10): : 599 - 604
  • [44] Time trends in utilization of G-CSF prophylaxis and risk of febrile neutropenia in a Medicare population receiving adjuvant chemotherapy for early-stage breast cancer
    Ravi K. Goyal
    Spiros Tzivelekis
    Kenneth J. Rothman
    Sean D. Candrilli
    James A. Kaye
    Supportive Care in Cancer, 2018, 26 : 539 - 548
  • [45] Assessing febrile neutropenia outcomes in patients receiving primary versus secondary prophylactic G-CSF treatment therapy with intermediate neutropenic risk chemotherapy regimens
    Goodin, Claire
    Ratliff, Patrick
    Cottingham, Lauren
    Shely, Ryan
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (07) : 1568 - 1572
  • [46] Time trends in utilization of G-CSF prophylaxis and risk of febrile neutropenia in a Medicare population receiving adjuvant chemotherapy for early-stage breast cancer
    Goyal, Ravi K.
    Tzivelekis, Spiros
    Rothman, Kenneth J.
    Candrilli, Sean D.
    Kaye, James A.
    SUPPORTIVE CARE IN CANCER, 2018, 26 (02) : 539 - 548
  • [47] Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy—a representative sample survey in Germany
    Hartmut Link
    J. Nietsch
    M. Kerkmann
    P. Ortner
    Supportive Care in Cancer, 2016, 24 : 367 - 376
  • [48] Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy-a representative sample survey in Germany
    Link, Hartmut
    Nietsch, J.
    Kerkmann, M.
    Ortner, P.
    SUPPORTIVE CARE IN CANCER, 2016, 24 (01) : 367 - 376
  • [49] Febrile neutropenia after hematopoietic stem cell mobilization with chemotherapy and G-CSF does not affect collection of adequate numbers of CD34+ cells.
    Yee, K
    Tu, JV
    MacKinnon, J
    Gandhi, M
    Stewart, AK
    Saragosa, R
    Keating, A
    Crump, M
    BLOOD, 1997, 90 (10) : 943 - 943
  • [50] Economic comparison of home-care-based versus hospital-based treatment of chemotherapy-induced febrile neutropenia in children
    Raisch, DW
    Holdsworth, MT
    Winter, SS
    Hutter, JJ
    Graham, ML
    VALUE IN HEALTH, 2003, 6 (02) : 158 - 166
12345